Results for tag: "Alport Syndrome Drug"

Alport Syndrome is a rare genetic disorder that affects the kidneys and hearing. It is caused by mutations in the COL4A5 gene, which is responsible for producing type IV collagen, a protein found in the basement membrane of the kidneys and inner ear. As a result, patients with Alport Syndrome experience progressive kidney failure and hearing loss. The Alport Syndrome Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs that are used to treat the symptoms of Alport Syndrome, such as kidney failure, hearing loss, and proteinuria. These drugs are typically prescribed by nephrologists and otolaryngologists. The Alport Syndrome Drug market is highly competitive, with many companies offering treatments for the disorder. Some of the major players in the market include AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Other companies, such as Amgen, Biogen, and Merck, are also active in the market. Show Less Read more